Bladder cancer combo trial halted after only 4 patients
NCT ID NCT04856189
First seen Feb 01, 2026 · Last updated May 01, 2026 · Updated 11 times
Summary
This study tested a combination of two drugs, selinexor and pembrolizumab, in people with advanced bladder cancer who could not take or had stopped responding to the chemotherapy drug cisplatin. The goal was to find the best dose and see if the combination could shrink tumors. However, the trial was stopped early after enrolling only 4 participants, so results are very limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC UROTHELIAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of California Davis Comprehensive Cancer Center
Sacramento, California, 95817, United States
Conditions
Explore the condition pages connected to this study.